PTIX at a glance
The past year
Chart−77.4% $0.46, close Nov 17
- From the highest close
- −79.8%
- Vs the 200-day average
- −19.6%
Short interest
History12,907 shares
- Since the last report
- −0.3%
- Days to cover
- 6.6 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
PTIX price history
Loading recent earnings…
Investment thesis
What must happen next
PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company.WeakeningMateriality: High
GAAP annual revenue was $0.0 in FY2026, confirming PTIX is still pre-commercial. If validation arrives, the equity can be valued as a drug-development option; if it does not, the company remains a cash-burning shell around uncertain science.
Watch: A disclosed failure of the lead neuropsychiatric program to show a credible biological or clinical signal would remove the core source of option value.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $0.0 in FY2026, confirming PTIX is still pre-commercial.
Open source ↗The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes.HoldingMateriality: High
Cash was $1.509 million at FY2026 year-end, up from $14,531 at FY2025 year-end. Adequate runway preserves upside to future data or partnerships, while inadequate runway can force punitive dilution or restructuring before the thesis can be tested.
Watch: A move into more expensive internally funded clinical work without a partner or financing would shorten runway before data can arrive.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $1.509 million at FY2026 year-end, up from $14,531 at FY2025 year-end.
Open source ↗Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support.WeakeningMateriality: Medium
GAAP annual operating cash flow was negative $2.807 million in FY2026. Expense discipline extends the time available for a scientific catalyst; fixed-cost escalation would increase dilution risk even if the pipeline remains scientifically plausible.
Watch: Launching a larger internally funded trial without non-dilutive capital would make the cost base less flexible.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $2.807 million in FY2026.
Open source ↗PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress.StrengtheningMateriality: Medium
Stockholders’ equity was positive $2.619 million at FY2026 year-end after being negative $4.953 million at FY2025 year-end. A fundable capital structure lets shareholders participate in successful data; a stressed structure can transfer value to financiers through discounts, warrants, or senior claims.
Watch: Issuing deeply discounted equity, convertible debt, or warrant-heavy financing would indicate the capital structure is still extracting value from common shareholders.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity was positive $2.619 million at FY2026 year-end after being negative $4.953 million at FY2025 year-end.
Open source ↗Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business.StrengtheningMateriality: Medium
GAAP annual operating income was negative $4.504 million in FY2026 despite GAAP annual net income of positive $1.368 million. If profitability is non-operating or episodic, valuation should remain anchored to pipeline probability and runway rather than earnings power.
Watch: A licensing or collaboration agreement with recurring economics would begin to create operating validation rather than one-time accounting gains.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income was negative $4.504 million in FY2026 despite GAAP annual net income of positive $1.368 million.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company. If validation arrives, the equity can be valued as a drug-development option; if it does not, the company remains a cash-burning shell around uncertain science.
The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes. Adequate runway preserves upside to future data or partnerships, while inadequate runway can force punitive dilution or restructuring before the thesis can be tested.
Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support. Expense discipline extends the time available for a scientific catalyst; fixed-cost escalation would increase dilution risk even if the pipeline remains scientifically plausible.
PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress. A fundable capital structure lets shareholders participate in successful data; a stressed structure can transfer value to financiers through discounts, warrants, or senior claims.
Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business. If profitability is non-operating or episodic, valuation should remain anchored to pipeline probability and runway rather than earnings power.
All standing thesis claims
Original report summary
PTIX is not yet a commercial drug company; it is a financing- and evidence-dependent biotech option whose value turns on whether its stress-related neuropsychiatric pipeline can produce credible validation before cash burn and dilution.
Bull case and bear case
Bull case and bear case for Protagenic Therapeutics, Inc.\new
Where the evidence on Protagenic Therapeutics, Inc.\new disagrees: Mixed on the latest evidence (Nov 19, 2026). Of its 5 thesis points, 2 strengthening, 1 holding and 2 weakening.
Bull case: what the evidence supports
The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes.
PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress.
Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business.
Bear case: what the evidence questions
PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company.
Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support.
Thesis-Break Engine
Thesis-break watch · Protagenic Therapeutics, Inc.\new
No break has crossed Protagenic Therapeutics, Inc.\new’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-11-17: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-11-06: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-08-20: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A disclosed failure of the lead neuropsychiatric program to show a credible biological or clinical signal would remove the core source of option value.
- A move into more expensive internally funded clinical work without a partner or financing would shorten runway before data can arrive.
- Launching a larger internally funded trial without non-dilutive capital would make the cost base less flexible.
- Issuing deeply discounted equity, convertible debt, or warrant-heavy financing would indicate the capital structure is still extracting value from common shareholders.
- A licensing or collaboration agreement with recurring economics would begin to create operating validation rather than one-time accounting gains.
PTIX news
Loading headlines…
Financial statements
PTIX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
PTIX: quick answers
- What is PTIX's short interest?
- As of October 30, 2026, 12,907 PTIX shares were sold short, down 0.3% from the count before. At the stock's average daily volume that is 6.6 days to cover. FINRA publishes the count twice a month. PTIX short interest history

